Recap: RAPT Therapeutics Q3 Earnings
Portfolio Pulse from Benzinga Insights
RAPT Therapeutics (NASDAQ:RAPT) reported Q3 earnings with an EPS of $-0.82, missing estimates by 9.33% compared to the expected $-0.75. Revenue was unchanged from the same period last year. Previously, the company beat EPS estimates but saw a 2.8% share price drop the following day.
November 13, 2023 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
RAPT Therapeutics reported a Q3 EPS of $-0.82, missing the estimated $-0.75 by 9.33%, with no change in year-over-year revenue. Last quarter's EPS beat resulted in a 2.8% stock price decline the next day.
Missing earnings estimates typically leads to negative investor sentiment and can cause a short-term decline in stock price. RAPT's history of a price drop following a positive earnings beat suggests the market may react strongly to an earnings miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100